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Genentech, Inc.
What is it famous for? Terrifyingly
fast cloning — back in the days when
that was hard — and pioneering work
in the field of protein therapeutics.
More recently, it has become
somewhat infamous for allegedly
over-creative marketing techniques.
How did it start?  It began in 1976
with a meeting over a glass of beer
between Bob Swanson, then a bright
young venture capitalist, and Herb
Boyer (UCSF), who with Stan Cohen
(Stanford) had just performed some of
the key experiments of recombinant
DNA technology. The meeting is
now immortalized in a brass statue in
the new Founders’ Research Center.
Genentech was founded later that
year, and cloned human insulin and
human growth hormone in the late
1970s. The first public offering of
Genentech stock, in 1980, was
greeted with wild enthusiasm.
When did it start to produce drugs?
Genentech’s first-born products had
to be licensed to other companies to
make ends meet. Recombinant
human insulin was licensed to Eli
Lilly and Co. in 1982, and the clotting
factor Factor VIII was licensed to
Cutter Biological in 1984. The first
product marketed by Genentech (and
the first by any biotechnology
company) was human growth
hormone, which was approved for the
treatment of children with growth
hormone inadequacy in 1985. Other
products include tissue plasminogen
activator (t-PA, which dissolves the
clot in heart attack patients) and
DNase (which cleaves the DNA in
the sputum of cystic fibrosis patients,
making it less viscous and easier to
remove from the lungs).
What makes Genentech’s success
possible?  The company has a huge
investment in scaled-up production of
proteins, and their main facility can
put out up to 50 kg of pure protein
per year. As well as this, Genentech
has spent 40–50% of its revenues on
research in recent years, much more
than is typical for a pharmaceutical
company. This emphasis on research
may be shifting, however, under the
scrutiny of Genentech’s new owners,
Roche; several senior scientists were
recently made redundant.
When did Roche get involved?  Roche
bought 50% of Genentech for $2 100
million in 1990, with an option to
purchase the remaining shares by
1995. The deadline has now been
extended to 1999; Roche currently
owns 68% of Genentech. Although
Genentech’s management is still
nominally independent, Roche’s
influence seems to be growing.
What’s so bad about their marketing?
Genentech has been accused of
encouraging the use of human growth
hormone in children who are only
normally short, not growth-hormone
deficient — a charge that the
company naturally denies. And there
has been considerable controversy
over the question of whether t-PA, a
costly human protein produced in
mammalian cell culture, is in fact any
more effective than a bacterially
derived product, streptokinase, which
costs a tenth of the price. A huge trial
recently showed that streptokinase
was good, but t-PA was better.
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In their recent Dispatch [1], Mark
Feinberg and Angela McLean rightly
point out that there have been two
unproven assumptions about human
immunodeficiency virus-1 (HIV-1)
pathogenesis: that cytotoxic (CD8) T
lymphocyte (CTL) activity is
important in regulating viral load, and
that failure of this activity leads to loss
of viral control and progression to
AIDS. They themselves, however,
make two further assumptions about
this disease: that the virus itself is
responsible for the death of infected
cells, and that any CTL-mediated
killing should limit, rather than
promote, death of helper T cells.
It is important to consider the
possibility that HIV infection in man
causes cell and tissue destruction not
directly, but indirectly via the
induced immune response [2].
Although HIV-1 isolates may cause
cell destruction in vitro, this has yet to
be morphologically demonstrated in
vivo. Lymphocytic choriomeningitis
virus (LCMV) may also cause
cytopathic effects in cultured cells,
but is a clear example of a virus which
is non-cytopathic in vivo in its natural
hosts (mouse and hamster) [3]. In
addition, the development of CTL
escape mutants that has been
documented in HIV-1 [4], has only
been observed elsewhere in viruses
that are non-cytopathic in their
respective hosts, notably LCMV,
Hepatitis B virus (HBV) and human
T-cell leukemia virus-1 [5–7]. Finally,
although cytopathic viruses induce a
very rapid neutralizing antibody
response, non-cytopathic viruses may
fail to do so. In this respect, HIV-1
follows the pattern of HBV and
LCMV, where neutralizing antibody
arises 60–150 days after infection, at a
time when most of the virus has been
cleared [8]. For LCMV this delay
may be ascribed to a sophisticated
virus–host relationship: B cells
producing neutralizing antibody, but
not B cells producing antibodies
specific for viral internal proteins, are
infected early by virus, and become
targets for lysis by virus-specific CTL
[8]. This mechanism, which facilitates
long-term viral persistence, may
apply in HBV and HIV-1.
Although LCMV itself is non-
cytopathic in vivo, it may, like HIV-1,
induce a state of immunosuppression
Magazine R403
[9]. In the mouse, this is mediated by
antiviral cytolytic CD8 T cells, but
various soluble factors, including
tumour necrosis factor and
interferon γ may also be involved in
this immunopathology — observed
histologically as destruction of
antigen-presenting cells and
follicular architecture [10,11].
The overall outcome, even in this
relatively simple system, is highly
variable, and point mutations in the
viral genome that alter growth rate or
tropism may have a huge effect. At the
one extreme, an early and efficient
CTL response may lead to low viral
loads and little immunopathology,
whereas at the other a state of high
viral load and immunological tolerance
may be observed. Between these two,
a combination of widespread virus and
active CTL responses can lead to a
progressive immune-mediated
pathology within the lymphoid system
itself. Thus, the same CTL response
may be protective, destructive or
apparently totally ineffective,
depending on the dose, kinetics of
growth and distribution of the virus.
The practical implications of this are
that boosting CTL activity at a time of
high viral load may cause
enhancement of disease, and that such
CTL responses might also render
induction of protective neutralizing
antibody responses difficult, through
lysis of B cells.
At the conclusion of their article,
the authors consider two possibilities:
that progression to AIDS has little to
do with failure of immune
surveillance, and that clearance of
infected cells has little to do with
CTL activity, at least as it is currently
measured. Perhaps we should add a
third possibility, that CTL-mediated
killing may contribute to both
immune surveillance and clearance of
infected cells in vivo, but that the
outcome may be very finely
balanced, as illustrated by LCMV
infection of the mouse.
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In their comment on our recent
Dispatch [1], Drs Zinkernagel and
Klenerman advance the hypothesis
that the immunodeficiency
associated with HIV-1 infection may
— as can be seen in certain models
of experimental LCMV infection —
be due to inadvertent destruction of
immune cells and tissues by the host
antiviral CTL response. A
fundamental underpinning of their
analogy between HIV-1 and LCMV
infections is the suggestion that
HIV-1 is, like LCMV, a non-
cytopathic virus.
We concur with their suggestion
that the specific anti-HIV-1 CTL
response may have indirect
consequences for the host, perhaps
contributing to an as yet unquantified
degree of CD4 T-cell loss, and
potentially giving rise to AIDS-
associated conditions such as wasting
and dementia. We also agree that a
better understanding of the balance
that determines whether host
antiviral immune responses are
beneficial or detrimental is needed
(Fig. 1). But although the potential
indirect consequences of HIV-1
infection represent an important topic
for further study, we believe strongly
that the weight of evidence indicates
that HIV-1 is, in fact, a cytopathic
virus that can cause direct destruction
of CD4 T cells both in tissue culture
and in vivo. Thus, at least in the
context in which it is raised, we
question the notion that LCMV is a
valid model for understanding the
immunopathogenesis of HIV-1
infection.
It is difficult to prove that a virus
is directly cytopathic in vivo,
particularly if infected cells are killed
and cleared rapidly. Although the
appearance of multinucleated giant
cells (syncytia) is taken as evidence
of the in vivo cytopathic effects of
herpes virus infections, this is
certainly not the only mechanism by
which viruses can induce cell death.
Indeed, syncytia have been seen in
lymphoid tissues and in the central
nervous system of HIV-1-infected
persons, although they are rare [2,3].
We believe that there is stronger
evidence for the direct (non-
immunologically mediated)
cytopathic effects of HIV-1 infection.
As discussed in our Dispatch [1],
HIV-1-infected cells live for only a
short period of time, there is little
variability between hosts in their rate
of clearance, and there is no
association between the lifespan of
R404 Current Biology, Vol 7 No 7
infected cells and the host’s
immunocompetence, as assessed by
CD4 T-cell count. Furthermore, the
appearance of HIV-1 variants with
more dramatic cytopathic
consequences in tissue culture
infections is associated with more
rapid decline in CD4 T-cell counts in
vivo, even though these typically
appear when immune function is
already substantially compromised [4].
Perhaps the best evidence against
the suggestion of Drs Zinkernagel
and Klenerman comes from studies
of infants who are infected with
HIV-1 at or near the time of birth.
Such perinatally-infected children
display extremely high levels of
HIV-1 replication (evidenced by high
plasma HIV-1 RNA levels), and
often progress to AIDS within the
first year or two of life. Perhaps as a
result of the immaturity of their
immune systems or the induction of
tolerance to HIV-1 in the setting of
neonatal exposure, perinatally-
infected infants often do not mount
detectable anti-HIV-1 CTL
responses. When they do so, it is
typically not until 6–12 months after
birth, a time when profound immune
deficiency is already manifest. By
contrast, in the LCMV model, where
the virus is non-cytopathic, neonatal
infection of mice leads to the
induction of immunologic tolerance,
high levels of chronic viremia, and
the absence of disease [5].
To address the balance between
beneficial and detrimental immune
responses discussed by Drs
Zinkernagel and Klenerman, we used
a simple mathematical model (Figure
1). During infection, the killing of
infected cells has two effects, on one
hand giving rise to fewer infected
cells, while on the other (through
reducing further rounds of infection)
giving rise to more uninfected cells.
The effect on the total number of
cells is therefore complex and hard to
predict from intuition alone.
Standard models of in vivo
infectious processes can aid in
understanding this apparent
complexity. They reveal that the
balance between beneficial and
detrimental effects of immune
killing of infected cells is strongly
conditioned by the magnitude of the
cytopathic effect of the virus itself.
There are three classes of outcome:
for totally non-cytopathic viruses,
immunopathology is always detri-
mental; for viruses of intermediate
cytopathicity, the immune-mediated
killing of infected cells must exceed
a certain threshold before it is
beneficial; and for highly cytopathic
viruses, any killing of infected cells is
beneficial. As the vast weight of
evidence indicates that HIV-1 can
kill infected cells in vivo, it must fall
into the second or third group.
LCMV, being non-cytopathic falls
into the first class and may, therefore,
not be the best available model for
immunopathology in HIV-1
infection.
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Figure 1
A crude measure of total immunopathology is
given by the total number of cells (of the type
susceptible to infection), infected+uninfected.
A beneficial CTL response is then one that
leads to more total cells at equilibrium than
there would be in the complete absence of
any CTL killing. A standard model of in vivo
infection counts target cells, T, and infected
cells, I. Target cells are produced at rate Λ
and both cell populations have natural death
rate δ. Cell–cell infection leads to the
generation of infected cells at rate bIT.
Infected cells have two additional death
rates: from the cytopathic effect of virus at
rate αI and from a CTL response at rate kEI.
These assumptions yield T
• 
= Λ – δT – bIT,
I
•
= bIT – (δ + α + kE)I. At equilibrium, the
number of target cells rises linearly as a
function of the rate of CTL killing and the
number of infected cells falls hyperbolically.
The sum gives a curve whose shape
depends upon the degree of cytopathic
effect of the virus. If we label as ‘Bad’, ‘Good’
and ‘Cure’ CTL responses that lead to fewer
cells overall, more cells overall, and viral
eradication, respectively, three types of
behaviour can be identified: (a–c). Plots
show equilibrium values of T+I with Λ = 5,
δ = 0.1, b = 0.03. The cytopathic effect of
the virus, α, takes a different value in each
plot: (a) α = 0; (b) α = 0.1; (c) α = 0.3.
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